​

Evolent Health (EVH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EVH Stock Forecast

Evolent Health (EVH) stock forecast, based on 27 Wall Street analysts, predicts a 12-month average price target of $22.50, with a high of $38.00 and a low of $14.00. This represents a 143.77% increase from the last price of $9.23.

$5 $12 $19 $26 $33 $40 High: $38 Avg: $22.5 Low: $14 Last Closed Price: $9.23

EVH Stock Rating

Evolent Health stock's rating consensus is Buy, based on 27 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 23 Buy (85.19%), 4 Hold (14.81%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 27 0 4 23 Strong Sell Sell Hold Buy Strong Buy

EVH Price Target Upside V Benchmarks

TypeNameUpside
StockEvolent Health143.77%
SectorHealthcare Stocks 33.91%
IndustryHealthcare Information Services Stocks 34.92%

Price Target Trends

1M3M12M
# Anlaysts--10
Avg Price Target--$28.90
Last Closing Price$9.23$9.23$9.23
Upside/Downside--213.11%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25481--13
Mar, 25581--14
Feb, 255101--16
Jan, 255101--16
Dec, 244101--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 16, 2025Kevin CaliendoUBS$14.00$9.9740.42%51.68%
Jan 15, 2025Jailendra SinghTruist Financial$20.00$9.97100.60%116.68%
Jan 14, 2025Sean DodgeRBC Capital$17.00$11.9642.14%84.18%
Jan 10, 2025Constantine DavidesJMP Securities$18.00$12.5443.54%95.02%
Nov 18, 2024Mohan NaiduOppenheimer$28.00$12.59122.40%203.36%
Oct 17, 2024Jeff GarroStephens$38.00$24.9652.24%311.70%
Aug 09, 2024Jailendra SinghTruist Financial$33.00$20.8758.12%257.53%
Jun 05, 2024Sean DodgeRBC Capital$42.00$22.0490.56%355.04%
May 14, 2024Jailendra SinghTruist Financial$28.00$23.7517.89%203.36%
Apr 17, 2024Jessica TassanPiper Sandler$51.00$29.6072.30%452.55%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 16, 2025UBSBuyBuyhold
Jan 14, 2025RBC CapitalOutperformOutperformhold
Jan 10, 2025JMP SecuritiesOutperformOutperformhold
Jan 10, 2025NeedhamBuyinitialise
Nov 18, 2024OppenheimerOutperformOutperformhold
Oct 10, 2024KeyBancOverweightinitialise
Oct 08, 2024StephensUnderperformUnderperformhold
Oct 03, 2024Cowen & Co.BuyBuyhold
Aug 19, 2024JMP SecuritiesUnderperformUnderperformhold
Jun 05, 2024RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.94$-0.35$-0.20$-1.28$-0.81----
Avg Forecast$-0.24$-0.04$0.86$0.78$0.72$0.78$1.08$1.09$1.52
High Forecast$-0.23$-0.04$0.90$0.95$0.83$1.45$8.52$1.32$1.84
Low Forecast$-0.25$-0.04$0.80$0.58$0.62$-0.19$-5.02$0.80$1.12
Surprise %1541.67%775.00%-123.26%-264.10%-212.50%----

Revenue Forecast

$500M $2B $3B $4B $5B $6B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.02B$907.96M$1.35B$1.96B$2.55B----
Avg Forecast$1.01B$890.15M$1.34B$1.95B$2.56B$2.49B$2.85B$3.57B$4.44B
High Forecast$1.04B$911.83M$1.39B$1.96B$2.97B$2.79B$2.90B$3.66B$5.16B
Low Forecast$979.36M$861.35M$1.27B$1.55B$2.55B$2.00B$2.80B$3.48B$3.54B
Surprise %1.02%2.00%0.70%0.71%-0.19%----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-334.25M$-30.28M$-18.70M$-113.04M$-93.45M----
Avg Forecast$-454.46M$-71.64M$95.83M$-142.26M$80.93M$70.06M$20.70M$117.60M$169.10M
High Forecast$-363.57M$-57.31M$100.19M$-113.81M$92.64M$160.88M$947.68M$146.31M$204.65M
Low Forecast$-545.35M$-85.96M$89.15M$-170.71M$69.21M$-20.76M$-558.89M$88.88M$124.33M
Surprise %-26.45%-57.73%-119.51%-20.54%-215.48%----

EVH Forecast FAQ

Is Evolent Health stock a buy?

Evolent Health stock has a consensus rating of Buy, based on 27 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 23 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Evolent Health is a favorable investment for most analysts.

What is Evolent Health's price target?

Evolent Health's price target, set by 27 Wall Street analysts, averages $22.5 over the next 12 months. The price target range spans from $14 at the low end to $38 at the high end, suggesting a potential 143.77% change from the previous closing price of $9.23.

How does Evolent Health stock forecast compare to its benchmarks?

Evolent Health's stock forecast shows a 143.77% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the healthcare information services stocks industry (34.92%).

What is the breakdown of analyst ratings for Evolent Health over the past three months?

  • April 2025: 30.77% Strong Buy, 61.54% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 35.71% Strong Buy, 57.14% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 31.25% Strong Buy, 62.50% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.

What is Evolent Health’s EPS forecast?

Evolent Health's average annual EPS forecast for its fiscal year ending in December 2025 is $0.78, marking a -196.30% decrease from the reported $-0.81 in 2024. Estimates for the following years are $1.08 in 2026, $1.09 in 2027, and $1.52 in 2028.

What is Evolent Health’s revenue forecast?

Evolent Health's average annual revenue forecast for its fiscal year ending in December 2025 is $2.49B, reflecting a -2.38% decrease from the reported $2.55B in 2024. The forecast for 2026 is $2.85B, followed by $3.57B for 2027, and $4.44B for 2028.

What is Evolent Health’s net income forecast?

Evolent Health's net income forecast for the fiscal year ending in December 2025 stands at $70.06M, representing a -174.97% decrease from the reported $-93.454M in 2024. Projections indicate $20.7M in 2026, $117.6M in 2027, and $169.1M in 2028.